HC Wainwright Issues Positive Forecast for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Greenwich LifeSciences in a report released on Wednesday, February 4th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.30) per share for the quarter, up from their prior estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.21) EPS.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its earnings results on Friday, November 14th. The company reported ($0.30) EPS for the quarter, meeting analysts’ consensus estimates of ($0.30).

GLSI has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Wall Street Zen upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $47.50.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $29.00 on Monday. The firm has a market cap of $401.80 million, a price-to-earnings ratio of -19.86 and a beta of 1.48. The firm has a 50 day simple moving average of $20.10 and a 200-day simple moving average of $13.83. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC increased its holdings in shares of Greenwich LifeSciences by 52.1% in the 3rd quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock valued at $208,000 after acquiring an additional 7,174 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Greenwich LifeSciences by 4.9% in the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after purchasing an additional 13,179 shares in the last quarter. Marshall Wace LLP acquired a new position in Greenwich LifeSciences in the second quarter valued at approximately $509,000. Geode Capital Management LLC increased its stake in Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after purchasing an additional 1,972 shares during the last quarter. Finally, Strs Ohio acquired a new stake in Greenwich LifeSciences during the first quarter worth approximately $177,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel acquired 1,800 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was acquired at an average cost of $29.83 per share, with a total value of $53,694.00. Following the transaction, the chief executive officer owned 5,604,102 shares in the company, valued at approximately $167,170,362.66. This trade represents a 0.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 20,600 shares of company stock valued at $378,669. 51.47% of the stock is currently owned by company insiders.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.